MP44: Prostate Cancer: Detection & Screening II

Poster Session Moderator(s)

• 

  William Catalona, Dr. (he/him/his)

  Professor of Urology
  Northwestern University Feinberg of Medicine
• 

  Arturo Mendoza-Vald�s, MD (he/him/his)
• 

  Francesco Montorsi

  Full Professor of Urology
  Vita Salute San Raffaele University, Milan, Italy

Presentations:

• 3:30 PM – 5:30 PM CST

  MP44-01: Optimal Sequencing of MRI and Prostate Health Index as Risk Stratification Tools in a Biomarker-Imaging Prostate Cancer Screening Pathway
  

  Poster Presenter: Woon Chau Tsang
• 3:30 PM – 5:30 PM CST

  MP44-02: Systematic and MRI-targeted biopsy strategies for the detection of radiorecurrent prostate cancer: an analysis from the FOcal RECurrent Assessment and Salvage Treatment (FORECAST) trial
  

  Poster Presenter: Alexander Light, MBBS,MRCS,BSc (Hons)
• 3:30 PM – 5:30 PM CST

  MP44-03: PI-RADS 5 Lesions within the Transition Zone are associated with decreased detection of Clinically Significant Prostate Cancer versus Peripheral Zone lesions in patients undergoing MRI Fusion Prostate Biopsy
  

  Poster Presenter: Andrew M. Wood, MD
• 3:30 PM – 5:30 PM CST

  MP44-04: Importance of the ultrasound characteristics of regions of interest by MRI and the additional target biopsy around their peri-hypoechoic lesions in MR/TRUS software fusion biopsy to improve detection rate of prostate cancer
  

  Poster Presenter: Danbee Lee, MD (she/her/hers)
• 3:30 PM – 5:30 PM CST

  MP44-05: Serum PSA trends and prostate cancer detection on follow-up in men with a prior negative biopsy: a cohort study
  

  Poster Presenter: Rajeev Kumar, MCh, FAMS
• 3:30 PM – 5:30 PM CST

  MP44-06: Tumor characteristics of multiparametric MRI-detected and -undetected lesions in patients with suspected radiorecurrent prostate cancer: an analysis from the FOcal RECurrent Assessment and Salvage Treatment (FORECAST) trial
  

  Poster Presenter: Alexander Light, MBBS,MRCS,BSc (Hons)
• 3:30 PM – 5:30 PM CST

  MP44-07: Inter-intrareader assessments with PI-RADS version 2.1 from MRI/TRUS software fusion prostate biopsy
  

  Poster Presenter: Won Hoon Song, MD – Pusan National University Yangsan Hospital
• 3:30 PM – 5:30 PM CST

  MP44-08: Relationship Between Covid 19 Vaccination and PSA level
  

  Poster Presenter: David T. Ahlborn, MD (he/him/his)
• 3:30 PM – 5:30 PM CST

  MP44-09: Can MRI Replace Repeat Biopsy in Men with Multifocal High Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation?
  

  Poster Presenter: Michael Sessine, MD,MBA – Wayne State University Department of Urology
• 3:30 PM – 5:30 PM CST

  MP44-10: The Value of Dynamic Contrast Enhancement for Risk-Stratification and Prostate Cancer Detection on Multiparametric Prostate MRI
  

  Poster Presenter: Eric V. Li, MD (he/him/his)
• 3:30 PM – 5:30 PM CST

  MP44-11: Detection of subsequent clinically significant prostate cancer following initial decision to forgo biopsy in the multiparametric MRI era
  

  Poster Presenter: Eric V. Li, MD (he/him/his)
• 3:30 PM – 5:30 PM CST

  MP44-12: mpMRI-targeted biopsy compared to systematic TRUS biopsy for men at risk for prostate cancer: 2 year follow up data and economic analysis.
  

  Poster Presenter: Laurence H. Klotz, MD – Sunnybrook Health Sciences Centre
• 3:30 PM – 5:30 PM CST

  MP44-13: Genetic Risk Assessment of Lethal Prostate Cancer Using Benign Prostatic Hyperplasia or prostate volume-related Polygenic Risk Score and Hereditary Cancer Susceptibility genes
  

  Poster Presenter: Rong Na, PhD (he/him/his) – The University of Hong Kong
• 3:30 PM – 5:30 PM CST

  MP44-14: Prebiopsy MRI approach for prostate cancer diagnosis is associated with lower risk of biochemical recurrence after treatment
  

  Poster Presenter: Fernando Blank Viadero, BS
• 3:30 PM – 5:30 PM CST

  MP44-15: The value of prostate-specific antigen density in long-term prostate cancer-mortality risk prediction
  

  Poster Presenter: Sara Yousef Yacoub, Medicine doctor (she/her/hers) – Karolinska University Hospital Huddinge
• 3:30 PM – 5:30 PM CST

  MP44-16: Non-infectious adverse events of transperineal prostate biopsies performed under local anesthesia in an outpatient setting – results from the NORAPP study
  

  Poster Presenter: Maciej Jacewicz, MD (he/him/his)
• 3:30 PM – 5:30 PM CST

  MP44-17: Use of Decipher prostate biopsy test in men with favorable risk disease undergoing conservative management in the SEER registry
  

  Poster Presenter: Alec Zhu, MD (he/him/his)
• 3:30 PM – 5:30 PM CST

  MP44-18: E3 ubiquitin-protein ligase, Tetratricopeptide Repeat Domain 3 (TTC3), H4 Clustered Histone 5 (H4C5), and epithelial cell adhesion molecule (EpCAM) are novel urine-enriched liquid biopsy biomarkers to detect prostate cancer in men
  

  Poster Presenter: Marcio Covas Moschovas, MD
• 3:30 PM – 5:30 PM CST

  MP44-19: Effects of prostate-specific antigen screening on prostate cancer incidence and mortality: a population-based cohort study in China
  

  Poster Presenter: Xiaohao Ruan, MBBS (he/him/his)
• 3:30 PM – 5:30 PM CST

  MP44-20: Male-Carriers of Gene Mutations associated with increased risk of Prostate Cancer: Results from a Single Institution Genetic Counseling Consultation
  

  Poster Presenter: Asier Leivar, MD – University Hospital La Paz